Is Biodesix, Inc. (BDSX) a Buy, Sell, or Hold?
Biodesix, Inc.
NASDAQ:BDSX
$21 USD
-$0.13 (-0.62%)
- Volume
- 46.16K
- Average Volume
- 76.31K
- Market Capitalization
- $170.95M
- P/E Ratio
- -5.17
- Dividend Yield
- 0.00%
- Price Target
- $27.00
- Year High
- $24.92
- Year Low
- $5.26
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.82
| Source | Headline |
|---|---|
|
Biodesix (BDSX) Surges 10.5%: Is This an Indication of Further Gains?
Biodesix (BDSX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term. zacks.com - 2026-06-19 05:31:02 |
|
Are Medical Stocks Lagging Biodesix (BDSX) This Year?
Here is how Biodesix, Inc. (BDSX) and BillionToOne (BLLN) have performed compared to their sector so far this year. zacks.com - 2026-06-15 10:41:24 |
|
3 Medical Service Industry Stocks Thriving Amid Workforce Challenges
BTSG, BDSX and HQY stand to benefit as digital health, healthcare analytics and nursing care growth offset workforce strains. zacks.com - 2026-06-08 09:26:27 |
|
Wall Street Analysts Believe Biodesix (BDSX) Could Rally 104.29%: Here's is How to Trade
The mean of analysts' price targets for Biodesix (BDSX) points to a 104.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. zacks.com - 2026-05-25 10:56:09 |
|
Biodesix to Participate in Upcoming Investor Conferences
LOUISVILLE, Colo., May 21, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that members of the Biodesix leadership team will participate in three upcoming investor conferences: globenewswire.com - 2026-05-21 06:00:00 |
|
Biodesix Announces ATS 2026 Presentations Providing Real-World Clinical Evidence and Healthcare System Economic Value for Nodify Lung® Testing Strategy
Includes real-world clinical data from Biodesix researchers and independent Healthcare Professionals Includes real-world clinical data from Biodesix researchers and independent Healthcare Professionals globenewswire.com - 2026-05-11 09:17:00 |
|
Does Biodesix (BDSX) Have the Potential to Rally 103.33% as Wall Street Analysts Expect?
The mean of analysts' price targets for Biodesix (BDSX) points to a 103.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. zacks.com - 2026-05-07 10:55:31 |
|
Biodesix, Inc. (BDSX) Q1 2026 Earnings Call Transcript
Biodesix, Inc. (BDSX) Q1 2026 Earnings Call Transcript seekingalpha.com - 2026-05-04 19:53:23 |
|
Biodesix, Inc. (BDSX) Reports Q1 Loss, Tops Revenue Estimates
Biodesix, Inc. (BDSX) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $1.26. This compares to a loss of $1.6 per share a year ago. zacks.com - 2026-05-04 18:10:21 |
|
Biodesix Announces First Quarter 2026 Results and Highlights
Delivered $25.6 million in revenue representing 42% growth in Q1 2026; Achieved 84% gross margin in Q1 2026; Increased FY 2026 Revenue Guidance to $108-114 million, mid-point reflects 25% growth; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Colo. globenewswire.com - 2026-05-04 16:01:00 |
|
Biodesix to Report First Quarter 2026 Financial Results on May 4, 2026
LOUISVILLE, Colo., April 20, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the first quarter ended March 31, 2026 after the close of trading on Monday, May 4. Biodesix management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. globenewswire.com - 2026-04-20 06:00:00 |
